CLOSE

Specials

  • March
  • June
  • September
  • Bioanalytical Services
  • Life Science Analytics
  • Life Science Compliance
  • Bioanalytical Services APAC
  • APAC
  • Europe

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
APAC
  • Home
  • News
  • Contributors
  • Magazine
  • Conferences
  • Newsletter
  • About

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Tollys Makes Philippe Goupit as Chairman of the Board

Tollys Makes Philippe Goupit as...

Immudex Releases dCode Dextramer Reagants

Immudex Releases dCode Dextramer...

How Biomarkers Impact Drug Discovery and Development

How Biomarkers Impact Drug Discovery...

Tecan Partners with QIAGEN to Automate Pre-analytical Processing of Blood Samples

Tecan Partners with QIAGEN to...

Why is Liquid Chromatography Coupled with Mass Spectrometry (LC-MS) Favored for Pharmaceutical Bioanalysis?

Why is Liquid Chromatography Coupled...

Proactive Strategies to Keep Container Fleet Intact

Proactive Strategies to Keep...

Improving Access to Quality and Critical Care through Telemedicine

Improving Access to Quality and...

Bioanalytics- A New Ray of Hope

Bioanalytics- A New Ray of Hope

Tollys Makes Philippe Goupit as Chairman of the Board

Tollys Makes Philippe Goupit as...

Immudex Releases dCode Dextramer Reagants

Immudex Releases dCode Dextramer...

How Biomarkers Impact Drug Discovery and Development

How Biomarkers Impact Drug Discovery...

Tecan Partners with QIAGEN to Automate Pre-analytical Processing of Blood Samples

Tecan Partners with QIAGEN to...

Why is Liquid Chromatography Coupled with Mass Spectrometry (LC-MS) Favored for Pharmaceutical Bioanalysis?

Why is Liquid Chromatography Coupled...

Proactive Strategies to Keep Container Fleet Intact

Proactive Strategies to Keep...

Improving Access to Quality and Critical Care through Telemedicine

Improving Access to Quality and...

Bioanalytics- A New Ray of Hope

Bioanalytics- A New Ray of Hope

Clinical Potential of Combining AI and Decentralized Clinical Trials

By Life Sciences Review | Saturday, December 19, 2020
Tweet

Leveraging AI and DCTs has become the core imperative to developing safe therapies as fast as possible.


FREMONT, CA: For years, enhancing clinical trial outcomes has focused on lowering time and cost. That focus, and the challenges of a pandemic, has triggered the digitization of the clinical trial life cycle. Decentralized Clinical Trials (DCTs), which put the patient at the heart of the trial experience and combine digital technologies, and artificial intelligence (AI), are joining forces to transform clinical research. Organizations are coupling DCT methodologies with AI in innovative means to reshape workflows across the clinical lifecycle, from trial design and patient recruitment to evidence generation. They are seeing dramatic decreases in time and cost of clinical studies. Read on to know more.


With the analytical tools and AI, the industry can benefit from this rich data to optimize patient recruitment, boost patient retention, reduce timelines, and maximize study results in future trials. AI can expedite target validation, trial design, and patient identification. DCTs can reduce the time and cost of clinical studies by widening patient access and retention due to enabling patients to participate safely and conveniently in their homes. 


DCTs also mitigate geographic, transportation, costs, and other hurdles that can enhance participants' diversity. The net impact is an enhancement in data quality as site-based transcription is avoided, plus an increase in efficiency for patients, sites, and study teams. Together, AI and DCTs can be a powerful tool.


To deploy AI with purpose, AI engines need more than just mountains of data. To offer accuracy, the data requires to be closely representative of the target population. As has been highly publicized in recent months, conventional clinical trials are often comprised of participants from urban areas and are predominantly white. DCTs drive AI engines since they inherently gather massive real-world, real-time data from diverse patient populations more inclusive of the world. By coupling both innovations, firms will enhance three crucial clinical trials, including trial design, patient recruitment, and evidence generation. AI’s continued maturation will widen its use across all stages of the patient journey and will lead to incredible breakthroughs in personalized medicine to rare diseases.


Check out: Top eClinical Trial Management Solution Companies


Weekly Brief

loading
Towards a New World Order
> <
  • Other 2021

    Top Vendors

    Current Issue
  • Other 2020

    Top Vendors

    Current Issue

Read Also

Top Biotech Developments to Watch for

Top Biotech Developments to Watch for

Importance of Biomarkers in Drug Development

Importance of Biomarkers in Drug Development

Using AI to Prevent Adverse Effects of Immunotherapy

Using AI to Prevent Adverse Effects of Immunotherapy

Ehave, Inc. Uses Artificial Intelligence And Machine Learning for Big Data Management in Mental Health Care

Ehave, Inc. Uses Artificial Intelligence And Machine Learning for Big Data Management in Mental Health Care
The Role of Technology in the Biotech Sector

The Role of Technology in the Biotech Sector

Why Partner with Bioanalysis Experts?

Why Partner with Bioanalysis Experts?

Cyberattacks in Hospitals

Cyberattacks in Hospitals

Principles of Sustainability in Pharmaceutical Packaging

Principles of Sustainability in Pharmaceutical Packaging
Loading...

Copyright © 2021 Life Science Review . All rights reserved. |  Subscribe follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/clinical-potential-of-combining-ai-and-decentralized-clinical-trials--nwid-212.html